Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astaxanthin-rich Phaffia rhodozyma extract is derived from the yeast *Phaffia rhodozyma* (now known as *Xanthophyllomyces dendrorhous*), a significant natural source of the potent antioxidant carotenoid, astaxanthin. [7, 8] Astaxanthin is the primary active component, making up approximately 80% of the total carotenoid content in the yeast. [6] The extract is utilized as a nutraceutical and dietary supplement for human consumption, and as a feed additive in aquaculture to pigment the flesh of farmed salmon and trout. [6, 7, 12, 18] The primary mechanism of action is its powerful antioxidant property, where astaxanthin neutralizes free radicals and reactive oxygen species, protecting cells from oxidative damage. [1, 2, 4, 5] Research has explored its anti-inflammatory, immune-modulating, and anti-cancer properties. [1, 2, 5] A preclinical study in a rat model of benign prostatic hyperplasia (BPH) showed the extract inhibited BPH development at a level comparable to finasteride, suggesting it could be a potential alternative therapy. [10, 13, 15] However, in a separate study on a rat model of prostate cancer, the extract did not show any chemopreventive activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on astaxanthin-rich Phaffia rhodozyma extract.